Last reviewed · How we verify

Diphtheria-tetanus-acellular pertussis vaccine

CanSino Biologics Inc. · Phase 1 active Biologic

Diphtheria-tetanus-acellular pertussis vaccine is a Biologic drug developed by CanSino Biologics Inc.. It is currently in Phase 1 development. Also known as: Boostrix vaccine.

At a glance

Generic nameDiphtheria-tetanus-acellular pertussis vaccine
Also known asBoostrix vaccine
SponsorCanSino Biologics Inc.
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Diphtheria-tetanus-acellular pertussis vaccine

What is Diphtheria-tetanus-acellular pertussis vaccine?

Diphtheria-tetanus-acellular pertussis vaccine is a Biologic drug developed by CanSino Biologics Inc..

Who makes Diphtheria-tetanus-acellular pertussis vaccine?

Diphtheria-tetanus-acellular pertussis vaccine is developed by CanSino Biologics Inc. (see full CanSino Biologics Inc. pipeline at /company/cansino-biologics-inc).

Is Diphtheria-tetanus-acellular pertussis vaccine also known as anything else?

Diphtheria-tetanus-acellular pertussis vaccine is also known as Boostrix vaccine.

What development phase is Diphtheria-tetanus-acellular pertussis vaccine in?

Diphtheria-tetanus-acellular pertussis vaccine is in Phase 1.

Related